Remove 2018 Remove Clinic Remove Community Remove Specialization
article thumbnail

Episode 148: Antiracism in Medicine Series Episode 4 – Dismantling Race-Based Medicine Part 2: Clinical Perspectives

The Clinical Problem Solvers

Nwamaka Eneanya and Jennifer Tsai to discuss the limitations and harms of race-based medicine in clinical practice. Our guests explain how we can incorporate race-conscious medicine in clinical settings, medical education, and biomedical/epidemiological research to responsibly recognize and address the harms of racial inequality.

Clinic 52
article thumbnail

Episode 262: Anti-Racism in Medicine Series – Episode 18 – Remedying Health Inequities Driven by the Carceral System

The Clinical Problem Solvers

Our guests remind us to think critically about our role in the carceral system and in imposing systems of control and punishment within clinical settings. The ways to remedy the negative impacts of incarceration are to incarcerate fewer people and to invest in communities. Hastings Cent Rep. 2022 03; 52 Suppl 1:S21-S23. PMID: 35470879.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

At Long Last, FDA Unveils Plan for Rare Disease Innovation Hub

FDA Law Blog

Peter Marks at James Valentine ’s FDA Rare Disease Town Hall session at the DIA Annual Meeting last month (see Pink Sheet coverage here ), this Hub is intended to serve as the Center of Excellence that we in the rare disease community have been calling for its establishment over the last several years.

article thumbnail

Critics Suggest FDA Approving Aduhelm Will Erode the “Public Trust”: What About Patients’ Trust?

FDA Law Blog

For 6 years, I served as a patient liaison within FDA in what was then called the Office of Special Health Issues. Over the years, this function expanded to cancer (renamed the Office of AIDS and Special Health Issues) and, ultimately, all serious and life-threatening diseases (dropping the AIDS nomenclature).

article thumbnail

Telemedicine and the Prescribing of Controlled Substances After the End of The Covid-19 Pandemic Emergency: DEA Announces Two Significant Proposed Rules: Read the Summary Below, But Learn All the Details and More at HPM’s Webinar on March 23, 2023 (Details Forthcoming….)

FDA Law Blog

While no “special registration” will yet be required to engage in telemedicine prescribing of controlled substances, DEA is proposing parameters to guide the practice of telemedicine encounters in a post-COVID world. The Act also established new definitions for “Internet,” “online pharmacy,” “practice of telemedicine,” among others.

article thumbnail

Rethinking Opioid Conversions: Mary Lynn McPherson and Drew Rosielle

GeriPal

It depends on the clinical situation. So, Dr. McPherson, as far as I can tell, she’s really the only person in our professional community who in any sort of serious public way said, folks we need to do something about this. But we still, regardless of how you do this calculation have to temper it with clinical judgment.

IT 139
article thumbnail

Nurse Practitioners Critical in Treating Older Adults as Ranks of Geriatricians Shrink

Physician's Weekly

The Health Resources and Services Administration projects a 50% increase in demand for geriatricians from 2018 to 2030, when the entire baby boom generation will be older than 65. Their growth has bolstered primary care, and, like doctors, they can specialize in particular branches of medicine. ” In 27 states and Washington, D.C.,